Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Health Econ. 2019 Jan 29;28(4):517–528. doi: 10.1002/hec.3860

Appendix Table A7.

Composition of substitutable lung cancer drugs

Lung cancer
treatments
Average per-claim
payment ($)
Before integration After integration
Nab-paclitaxel $1,704 0.90% 4.26%
Gemcitabine $385 8.78% 14.45%
Docetaxel $119 9.01% 12.90%
Carboplatin $26 59.68% 43.10%
Etoposide $14 15.32% 10.45%
Paclitaxel $32 26.58% 21.29%

Notes:

The distribution of the drugs among lung cancer patients.